New results show that Edixomed’s revolutionary new wound care system, EDX110, can heal diabetic foot ulcers dramatically faster and more effectively than current standard care.
EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide. The findings of this study support the unique potential of EDX110’s core technology: a sustained-release nitric oxide generating platform, that can be delivered as a dressing, liquid, gel or inhaled spray, with potential application in a variety of serious, underserved conditions, such as antimicrobial resistance (AMR).
Results from the pivotal clinical study showed that in 12 weeks, EDX110 reduced ulcer size by almost double the amount standard-of-care achieved. EDX110 also increased the number of completely healed ulcers by more than 50%, nearly doubled the complete healing of infected ulcers and significantly reduced hospitalisations and serious adverse events related to the ulcer, compared with standard-of-care at 12 weeks.
Through its novel mode-of-action, Edixomed’s unique technology safely harnesses a key molecule in the body’s own defences, nitric oxide, to amplify the body’s own response in fighting infection. Laboratory tests have shown EDX110 rapidly and safely kills bacteria, viruses and fungi, including several deadly antibiotic-resistant infections, such as MRSA and E. Coli.
Professor Michael Edmonds, Principal Investigator, King’s College Hospital London said,“Diabetic foot ulcers are notoriously hard to heal, and are the leading cause of diabetes-related amputations in the UK. Reducing infection and accelerating healing could significantly contribute to a reduction in the number of avoidable amputations.”
Professor Chris Wood, Chief Medical Officer, Edixomed said, “Edixomed has developed an important solution to the problem of chronic would care and the major issue of antimicrobial resistance. This is a powerful and versatile core technology with many potential applications.”